Venus Remedies Secures Cancer Drug Approvals in Morocco, Philippines
By Rediff Money Desk, Chandigarh Sep 30, 2024 10:56
Venus Remedies has obtained marketing authorisations for carboplatin and bortezomib in Morocco and Philippines, respectively, expanding its oncology portfolio and presence in Southeast Asia and Africa.
Chandigarh, Sep 30 (PTI) Pharma major Venus Remedies Ltd on Monday said it has secured marketing authorisations for two key oncology drugs -- carboplatin and bortezomib -- from Morocco and Philippines, respectively.
"These approvals are pivotal in our strategy to expand our oncology range and meet the increasing global demand for cancer treatments. We are advancing toward becoming the leading oncology supplier in Southeast Asia," Saransh Chaudhary, president of Global Critical Care at Venus Remedies, said in a statement.
The Philippines market, the second largest in the ASEAN region, is expected to grow from USD 400 million in 2022 to USD 790 million by 2030. The authorisation of bortezomib will enhance the company's ability to deliver advanced cancer solutions in Southeast Asia, said the statement.
In Morocco, where the oncology drug market is set to reach USD 150.8 million by 2029, the approval of carboplatin will strengthen Venus Remedies' position in the African oncology market.
Aditi K Chaudhary, president of the company's international business, said, "These authorisations reflect our commitment to providing innovative and accessible healthcare solutions worldwide."
Panchkula-based Venus Remedies now holds 15 authorisations in Morocco and 69 in the Philippines.
"These approvals are pivotal in our strategy to expand our oncology range and meet the increasing global demand for cancer treatments. We are advancing toward becoming the leading oncology supplier in Southeast Asia," Saransh Chaudhary, president of Global Critical Care at Venus Remedies, said in a statement.
The Philippines market, the second largest in the ASEAN region, is expected to grow from USD 400 million in 2022 to USD 790 million by 2030. The authorisation of bortezomib will enhance the company's ability to deliver advanced cancer solutions in Southeast Asia, said the statement.
In Morocco, where the oncology drug market is set to reach USD 150.8 million by 2029, the approval of carboplatin will strengthen Venus Remedies' position in the African oncology market.
Aditi K Chaudhary, president of the company's international business, said, "These authorisations reflect our commitment to providing innovative and accessible healthcare solutions worldwide."
Panchkula-based Venus Remedies now holds 15 authorisations in Morocco and 69 in the Philippines.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.41 ( -4.74)
- 88551228
- Standard Capital
- 1.67 (+ 9.87)
- 58978942
- Spicejet Ltd.
- 61.36 (+ 4.02)
- 51198024
- Reliance Power L
- 48.67 (+ 4.98)
- 36476275
- Vodafone Idea L
- 10.46 ( -1.97)
- 24459413
MORE NEWS
ICAI Launches Stress Management Initiatives for...
ICAI sets up a stress management group and counselling help desk following the death of...
Greenzo Energy Wins Rs 1,200 Cr Hydrogen...
Greenzo Energy has secured a multi-crore hydrogen project from TANGEDCO, taking its...
L&T Wins Energy Management System Order...
Larsen & Toubro has secured an order to develop and implement energy management...